WO1999019364A1 - Dextrane a teneur reduite en bore, procede de production associe, et dextrane emballe dans un contenant a l'etat de solution - Google Patents
Dextrane a teneur reduite en bore, procede de production associe, et dextrane emballe dans un contenant a l'etat de solution Download PDFInfo
- Publication number
- WO1999019364A1 WO1999019364A1 PCT/JP1998/004541 JP9804541W WO9919364A1 WO 1999019364 A1 WO1999019364 A1 WO 1999019364A1 JP 9804541 W JP9804541 W JP 9804541W WO 9919364 A1 WO9919364 A1 WO 9919364A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dextran
- boron
- container
- boron content
- content
- Prior art date
Links
- 229920002307 Dextran Polymers 0.000 title claims abstract description 156
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 title claims abstract description 80
- 229910052796 boron Inorganic materials 0.000 title claims abstract description 77
- 238000000034 method Methods 0.000 title claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000000843 powder Substances 0.000 claims description 27
- 239000002994 raw material Substances 0.000 claims description 11
- 210000000689 upper leg Anatomy 0.000 claims description 2
- 238000003860 storage Methods 0.000 abstract description 6
- 238000001556 precipitation Methods 0.000 abstract description 4
- 239000012530 fluid Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 abstract 3
- 239000002504 physiological saline solution Substances 0.000 abstract 1
- 239000003058 plasma substitute Substances 0.000 abstract 1
- 230000001376 precipitating effect Effects 0.000 abstract 1
- 229960002086 dextran Drugs 0.000 description 142
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 239000013078 crystal Substances 0.000 description 10
- 239000000835 fiber Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000000151 deposition Methods 0.000 description 5
- 230000002950 deficient Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- 241001468194 Leuconostoc mesenteroides subsp. dextranicum Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 208000032450 Surgical Shock Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000036654 deficiency anemia Diseases 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
Definitions
- the present invention relates to a dextran containing a low amount of boron, a method for saturating the dextran, and a dextran filled in a container in a molten state.
- Dextran Sucrose is attractive to dextran-producing bacteria (Leuconostoc mesenteroides, Leuconostoc dextranicum, etc.). Dextran having an appropriate molecular weight among the dextran produced is dissolved in lJl ⁇ i & K, and this is dissolved in lateral teeth in the treatment of acute bleeding, ⁇ . Preventive agent for surgical shock based on bleeding, etc. , Or ⁇ ⁇ is used as an extracorporeal ⁇ fluid.
- dextran is used as a complex with iron (ftl ⁇ night described in fiber deficiency anemia), and dextran sulfate ester (heparin iDf field as anti-coagulant for dextran). Dextran is also used in various industrial fields such as the mouth and mouth industry.
- Dextran is performed through the M process shown in Fig. 2. That is, first, sucrose as a raw material, ⁇ ⁇ such as dipotassium phosphate, and vitamins are added to raw material fiber 1 together with water to dissolve the raw material, and then the raw material liquid is sent to ⁇ 2 and dextran is added. Producing bacteria are added and pulps. After difficulties, send ⁇ night to 3 and add methanol to separate dextran.
- ⁇ ⁇ such as dipotassium phosphate
- vitamins are added to raw material fiber 1 together with water to dissolve the raw material, and then the raw material liquid is sent to ⁇ 2 and dextran is added. Producing bacteria are added and pulps. After difficulties, send ⁇ night to 3 and add methanol to separate dextran.
- the dextran powder obtained in this manner is dissolved in 3 ⁇ 4ft_K as described above, for example, in the field, and is densely packed in a container for use at night or the like.
- dextrin obtained by dissolving dextrin obtained by the $ 3 ⁇ 4t method and dissolving it into a container may be dextran crystallized due to the change during storage.
- the dextran crystal is extracted during the dextran intense night. Dextran crystals once deposited (due to the dextran solution in which the crystals were precipitated because the dextran solution was difficult to re-dissolve even with the use of other means such as caloric temperature and temperature). Vessel (Ray to be discarded.
- an object of the present invention is to remove dextran, which is unlikely to precipitate crystals even when used at an intense night, a method thereof, and dextran which is liquid and is applied to a container5. Disclosure of the invention
- the inventors of the present invention have conducted repeated studies to obtain the above, and as a result, focused on the impurities contained in the dextran sig- naled by the method, and found that the impurities contained in the dextran were extracted. We thought that it would have an effect, but we did further research and, surprisingly, surprisingly, it had a function to reduce the precipitation of boron dextran contained in dextran. Knowledge was obtained. Based on such findings, the present inventors have further studied and found that the content of boron in dextran should be less than 0.30 ⁇ g Sg in the boron source as a stomach » As a result, the ability to precipitate crystals from the dextran solution was discovered.
- Boron content is less than 0.30 g / g based on boron Dextran with a delicate boron content.
- Boron-containing dextran is ⁇ M with a lower alcohol, and the boron content is reduced to less than 0.30 x g / g (mam) with boron source 3 ⁇ 4 ⁇ ! M, boron content iD Dextran
- Fig. 1 This is a schematic diagram showing the effect of boron on dextran.
- Figure 2 Flow sheet showing dextran presentation.
- the dextran of the present invention can be obtained by subjecting a boron-containing dextran, which is a raw material of the present invention, to 50% with a lower alcohol.
- a boron-containing dextran which is a raw material of the present invention
- Uegumo makes angle of boron contained in raw material dextran into ⁇ -grade alcohol? Wheat can be reduced to 5S by adding as needed.
- the dextran method of the present invention, the boron-containing dextran is keyed by a lower alcohol, and the boron content is less than 0.30 / zg / g in terms of boron.
- the boron-containing dextran used as an output material may be in the state of hard powder or hard night 5).
- the dextran of the present invention has a good dextran crystal deposition ability like the dextran itself and its precipitation power, it can be used to make a dextran night solution into a dextran night container, which is effective. Can shelving power.
- the present invention encompasses both the boron contained in the dextran and the compound containing a boron atom or a boron atom.
- boron may leak into the dextran solution.
- the medium contains boron as a minor component, it is unavoidable that it will be mixed with dextran, which is a substance, in some circumstances.
- the boron content of the dextran thus difficult is usually 0.30 to 1.20 gZ g ⁇ g (dry matter am) in terms of boron source.
- methanol is inverted, and the methanol in this S ⁇ tlS is dextran of the present invention, that is, the dextran of the present invention, that is, the boron content is You cannot get a dextran less than g / g.
- boron-containing dextran used as a raw material may be in powder form, or may be a furnace or dissolved in water.
- dextran may be separated from the lower alcohol by, for example, filtration, and then separated.
- the dextran is mixed with the raw material dextran powder, dissolved in lower alcohol as trialkyl borate, and separated from dextran.
- the washing of the dextran powder with the lower alcohol may be carried out only once, but it is repeated «times, but the boron content (the dextran» fi * is 0.30 g / boron conversion in terms of boron atoms per fi *). less than g). Also, it is only necessary to supply the ⁇ ⁇ -class ⁇ 1 ⁇ ⁇ 4 dextran, and there is no particular limitation.
- the dextran powder may be dissolved in a ⁇ -grade alcohol at room temperature while prevailing, or may be performed under warm or heated conditions.
- a dextran aggressive night may be used instead of the dextran powder.
- add lower alcohol to the dextran water on the night and do the same as above.
- 7Ut of the dextran during the night on the night (Lake 20 to 30S *% is good.
- the lower alcohol 04 should be about 1/2 to 1/3 by fimt-shadow against dextran water intense night.
- the boron content in dextran is It is less than 0.30 g / g, preferably less than 0.25 gZg, more preferably less than ⁇ ⁇ ⁇ ⁇ .20 zg / g.
- This dextran powder is dissolved together with other components in pure j, is sealed in a forehead such as a plastic bag or a glass vial, and can be used as a dextran such as 'night'.
- the concentration of dextran is 3-10% difficult.
- the boron content force filled in a container in the form of overnight storage «Dextran in storage ⁇ ! Dextran crystals are prevented from depositing on the inner wall of the container due to changes in the interior, etc., or the dextran crystals are deposited on the inner wall of the container.
- the relationship is not always clear, as shown schematically in FIG. 1, based on the lone pair of dextran, based on the lone pair of electrons in the radical
- the boron content in dextran is increased as described above, which is not due to the fact that dextran is easily precipitated. Strong dextran deposition power.
- Dextran powder in methanol was obtained in the same manner as in Example 1 except that 200 g of dextran powder was added to 200 ml of methanol.
- the dextran of the present invention was in S3 ⁇ 4IJ form (), and the following fibers were produced.
- the dextran in methanol was dissolved in the same manner as in Example 1 described in ⁇ 5 ⁇ above, and 10 w / V% dextran water ⁇ was observed.
- 50 ml of the dextran was placed in a 100 ml glass vial, sealed and filled into a container, and dextran was added.
- a dextran solution urn 2 filled in a container in the same manner as described above was prepared using dextran before methanol awakening (dextran having a number average molecular weight of 40,000, manufactured by Meito Sangyo Co., Ltd. described above).
- ⁇ is given to the fiber of ⁇ a (Fiber, and the numerator is the test where Nada was generated; the number is shown.
- Nada of Dextran s was not recognized in all words even 4 days after the first thigh in Word 1 using dextran whose boron content was reduced by methanol .
- the number of defectives generated with respect to the boron content in the dextran solution was checked.
- dextran powder was used in the same manner as described above using dextran powder (manufactured by Meito Sangyo Co., Ltd., dextran having a number average molecular weight of 40,000). I hate the container.
- the boron content in the control vessel is 1.20 ppm relative to the Si of the dextran.
- Table 4 is given to the common ⁇ fiber, and the numerator is the solid number generated by Nada.
- the deposition force is controlled by the dextran precipitation force. Therefore, the rate of occurrence of defective products can be suppressed or increased.For example, it is suitable for medical uses such as ( ⁇ * the dextran of the present invention, 43 ⁇ 4fe ⁇ K-melin syrup and body fluid).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- External Artificial Organs (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002306277A CA2306277C (en) | 1997-10-09 | 1998-10-07 | Dextran reduced in boron content, process for producing the same, and dextran packed in container in solution state |
US09/529,097 US6632939B2 (en) | 1997-10-09 | 1998-10-07 | Process for producing dextran reduced in boron content |
DE69838032T DE69838032T2 (de) | 1997-10-09 | 1998-10-07 | Dextran mit geringem borgehalt, verfahren zu deren herstellung und dextran in form einer lösung verpackt in einem behälter |
EP98947782A EP1024148B1 (en) | 1997-10-09 | 1998-10-07 | Dextran reduced in boron content, process for producing the same, and dextran packed in container in solution state |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP27778797 | 1997-10-09 | ||
JP9/277787 | 1997-10-09 | ||
JP17909698A JP4042813B2 (ja) | 1997-10-09 | 1998-06-25 | ホウ素の含有量が低減されたデキストランの製造方法 |
JP10/179096 | 1998-06-25 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/529,097 A-371-Of-International US6632939B2 (en) | 1997-10-09 | 1998-10-07 | Process for producing dextran reduced in boron content |
US09/277,787 Continuation US20020101846A1 (en) | 1996-09-27 | 1999-03-29 | Method for adapting a receiver to transmission conditions and a corresponding receiver |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999019364A1 true WO1999019364A1 (fr) | 1999-04-22 |
Family
ID=26499059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/004541 WO1999019364A1 (fr) | 1997-10-09 | 1998-10-07 | Dextrane a teneur reduite en bore, procede de production associe, et dextrane emballe dans un contenant a l'etat de solution |
Country Status (9)
Country | Link |
---|---|
US (1) | US6632939B2 (ja) |
EP (1) | EP1024148B1 (ja) |
JP (1) | JP4042813B2 (ja) |
AT (1) | ATE366262T1 (ja) |
CA (1) | CA2306277C (ja) |
DE (1) | DE69838032T2 (ja) |
ES (1) | ES2289794T3 (ja) |
PT (1) | PT1024148E (ja) |
WO (1) | WO1999019364A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5924795B2 (ja) | 2014-06-13 | 2016-05-25 | テンボロン オイ | 複合体 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54113488A (en) * | 1978-02-21 | 1979-09-05 | Green Cross Corp:The | Urokinase derivative and its preparation |
JPS5920301A (ja) * | 1982-07-27 | 1984-02-02 | Green Cross Corp:The | ウロキナ−ゼ・デキストラン誘導体の製造法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2644815A (en) * | 1948-10-15 | 1953-07-07 | Pharmacia Ab | Process for producing dextran products having substantially uniform molecular size for pharmaceutical and therapeutic preparations |
GB673103A (en) * | 1948-10-15 | 1952-06-04 | Pharmacia Ab | A process for treating dextran for use in pharmaceutical and therapeutical preparations |
US4208392A (en) | 1979-03-23 | 1980-06-17 | Nalco Chemical Co. | Two-step process for removing boron compounds from aqueous solutions of magnesium chloride |
JPH0436187A (ja) * | 1990-05-31 | 1992-02-06 | Sapporo Breweries Ltd | 抗腫瘍性デキストランの製造法 |
US5608306A (en) | 1994-03-15 | 1997-03-04 | Ericsson Inc. | Rechargeable battery pack with identification circuit, real time clock and authentication capability |
JPH09239000A (ja) | 1996-03-07 | 1997-09-16 | Otsuka Pharmaceut Factory Inc | デキストラン注射液充填容器およびその製造方法 |
-
1998
- 1998-06-25 JP JP17909698A patent/JP4042813B2/ja not_active Expired - Lifetime
- 1998-10-07 DE DE69838032T patent/DE69838032T2/de not_active Expired - Fee Related
- 1998-10-07 CA CA002306277A patent/CA2306277C/en not_active Expired - Fee Related
- 1998-10-07 WO PCT/JP1998/004541 patent/WO1999019364A1/ja active IP Right Grant
- 1998-10-07 PT PT98947782T patent/PT1024148E/pt unknown
- 1998-10-07 AT AT98947782T patent/ATE366262T1/de not_active IP Right Cessation
- 1998-10-07 EP EP98947782A patent/EP1024148B1/en not_active Expired - Lifetime
- 1998-10-07 ES ES98947782T patent/ES2289794T3/es not_active Expired - Lifetime
- 1998-10-07 US US09/529,097 patent/US6632939B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54113488A (en) * | 1978-02-21 | 1979-09-05 | Green Cross Corp:The | Urokinase derivative and its preparation |
JPS5920301A (ja) * | 1982-07-27 | 1984-02-02 | Green Cross Corp:The | ウロキナ−ゼ・デキストラン誘導体の製造法 |
Also Published As
Publication number | Publication date |
---|---|
CA2306277A1 (en) | 1999-04-22 |
US20030018010A1 (en) | 2003-01-23 |
US6632939B2 (en) | 2003-10-14 |
PT1024148E (pt) | 2007-07-25 |
ES2289794T3 (es) | 2008-02-01 |
EP1024148B1 (en) | 2007-07-04 |
EP1024148A4 (en) | 2000-12-20 |
DE69838032T2 (de) | 2008-03-06 |
DE69838032D1 (de) | 2007-08-16 |
CA2306277C (en) | 2006-11-07 |
EP1024148A1 (en) | 2000-08-02 |
JP4042813B2 (ja) | 2008-02-06 |
ATE366262T1 (de) | 2007-07-15 |
JPH11171902A (ja) | 1999-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7935271B2 (en) | Compositions, systems, and/or methods involving chlorine dioxide | |
JP2002502636A (ja) | 過酢酸および他の酸化剤の電気化学的合成 | |
JPS6289602A (ja) | 殺菌剤組成物 | |
US20220151870A1 (en) | Medicinal product comprising a container and an aqueous liquid containing bicarbonate | |
Ayo-Yusuf et al. | SEM–EDX study of prepared human dentine surfaces exposed to gingival retraction fluids | |
JPS60147287A (ja) | 飲料水改質剤 | |
WO1999019364A1 (fr) | Dextrane a teneur reduite en bore, procede de production associe, et dextrane emballe dans un contenant a l'etat de solution | |
CN107417024B (zh) | 一种医药化工污水处理工艺 | |
JPH02274253A (ja) | 殺ウイルス性血液袋系 | |
US20010043951A1 (en) | Polyphosphate for use in promoting wound healing and scar abatement | |
JP3288782B2 (ja) | 活性浴及び清澄浴用濃縮物及びこの濃縮物から得られた浴 | |
JPH0840711A (ja) | 水酸アパタイトの被膜の形成法 | |
JPH10500623A (ja) | 殺菌すべき物質をガスで処理した後のガスの形のエチレンオキシドを除毒処理するための方法 | |
CN105876298A (zh) | 用魔芋精粉制备葡甘露中和低聚糖液的方法 | |
JP5320980B2 (ja) | ガスバリア材 | |
US5628838A (en) | Concentrate for activating and defining bath and bath obtained from this concentrate | |
JPH08164186A (ja) | 還元糖と重炭酸を含有する一剤化された液剤の滅菌法 | |
JP3758975B2 (ja) | ダイス廃液の処理方法及び装置 | |
JP6210521B1 (ja) | 水素水 | |
GB353409A (en) | Improvements in and relating to the sterilisation of liquids | |
SU239789A1 (ru) | Поточный способ приготовлени виноградного сока высокого качества | |
CN116983450A (zh) | 一种高效型甲醛灭菌器及灭菌工艺 | |
JP2001161789A (ja) | 水性注射剤 | |
JPH0316692A (ja) | 無菌純水の供給方法 | |
Williams | An Hypothesis Concerning Bacteriophagy. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2306277 Country of ref document: CA Ref country code: CA Ref document number: 2306277 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998947782 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09529097 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998947782 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998947782 Country of ref document: EP |